Cancer Communications

Articles

Content type: Original article
| 24 June 2019

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Authors: Tianshu Liu, Yanru Qin, Jin Li, Ruihua Xu, Jianming Xu, Shujun Yang, Shukui Qin, Yuxian Bai, Changping Wu, Yixiang Mao, Haiyan Wu, Yilin Ge and Lin Shen
Content type: Letter to the Editor
| 21 June 2019

Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression

Authors: Jie Wang, Jianzhong Xi, Hanshuo Zhang, Juan Li, Yuchao Xia, Ruibin Xi and Zhijun Xi
Content type: Review
| 20 June 2019

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Authors: Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi…
Content type: Letter to the Editor
| 19 June 2019

Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer

Authors: Romano Demicheli, Marco Fornili, Patrizia Querzoli, Massimo Pedriali, Saverio Alberti, Christine Desmedt and Elia Biganzoli
Content type: Review
| 14 June 2019

Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

Authors: Jean-François Rossi, Patrice Céballos and Zhao-Yang Lu

Most recent articles RSS

View all articles

Content type: Review
| 2 July 2015

Predictive biomarkers in precision medicine and drug development against lung cancer

Authors: Bingliang Fang, Reza J Mehran, John V Heymach and Stephen G Swisher
Content type: Original article
| 10 August 2015

The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer

Authors: Xue-Yan Zhang, Ge Zhang, Ying Jiang, Dan Liu, Man-Zhi Li, Qian Zhong, Shan-Qi Zeng, Wan-Li Liu and Mu-Sheng Zeng
Content type: Original article
| 12 August 2015

Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system

Authors: Lu-Jun Shen, Si-Yang Wang, Guo-Feng Xie, Qi Zeng, Chen Chen, An-Nan Dong, Zhi-Mei Huang, Chang-Chuan Pan, Yun-Fei Xia and Pei-Hong Wu
Content type: Original article
| 15 August 2015

Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis

Authors: Huixin Ming, Ying Lan, Feng He, Xue Xiao, Xiaoying Zhou, Zhe Zhang, Ping Li and Guangwu Huang
Content type: Review
| 7 April 2016

Cell-free circulating tumor DNA in cancer

Authors: Zhen Qin, Vladimir A. Ljubimov, Cuiqi Zhou, Yunguang Tong and Jimin Liang

Most accessed articles RSS

View all articles

2018

Thematic series
Boron Neutron Capture Therapy of Cancer
Edited by Rolf F. Barth

2017

Thematic series
Tumor Metastasis
Edited by Jian Zhang and Chao-Nan Qian

2016

Thematic series
Gastric Cancer
Edited by Yun Dai and Li Yan

Thematic series
Tumor Angiogenesis
Edited by Francesco Pezzella and Chao-Nan Qian

2015

Thematic series
Lung Cancer
Edited by Lin Yan and Wei Zhang

Archival content

To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.

Important notice

We would like to inform you that Chinese Journal of Cancer has changed the title to Cancer Communications on 1^st March 2018.

Thematic series

Boron Neutron Capture Therapy of Cancer
Edited by Rolf F. Barth

Tumor metastasis
Edited by: Jian Zhang and Chao-Nan Qian

Aims and scope

Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.

Editor-in-Chief

Prof Rui-Hua Xu, Sun Yat-sen University Cancer Center, China

Information for authors

Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter.

Cancer Communications

Articles

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer

Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

Predictive biomarkers in precision medicine and drug development against lung cancer

The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer

Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system

Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis

Cell-free circulating tumor DNA in cancer

2018

2017

2016

2015

Archival content

Important notice

Thematic series

Aims and scope

Editor-in-Chief

Information for authors

Affiliated with

Follow

Annual Journal Metrics

Cancer Communications

Contact us